Rare cancer cells captured by imaging device

	Tweet

A microchip that captures and stores images of rare cancer cells circulating in the blood may provide a way to monitor patients after surgery and could eventually guide treatment, U.S. researchers said in a study published on Wednesday.

Circulating tumor cells, or CTCs, shed from a tumor like seeds and can grow into new tumors. The presence of CTCs in the blood might tip off doctors that a cancer could spread to other parts of the body, the researchers said in the journal Science Translational Medicine. CTCs might also help doctors quickly tell whether a patient is responding well to chemotherapy or other treatment.

“We’re very interested in these cells because we believe these are the ones that are going to give us the most insight into cancer biology as well as cues to how cancer metastasizes,” lead author Shannon Stott, of Massachusetts General Hospital and Harvard Medical School in Boston, said in a telephone interview.

With the help of a substance that works like biological “glue,” the microchip captures only the cells the researchers want to examine, Stott said. In this case it was the prostate specific antigen, which indicates the presence of prostate cancer. The device is coupled with a microscope which takes at least 6,000 images of the cells, Stott said.

“There’s no preprocessing. You just draw the blood and stick it through the device,” she said.

The hope is that the device will enable clinicians to learn more about tumors without having to cut into patients, Stott added.

“You could just do this blood test, so it’s like a blood biopsy to get insight into the biological properties of the tumor,” she said.

In the study, Stott and colleagues collected and, for the first time, counted circulating tumor cells from 55 cancer patients. The team monitored the cells before and after surgery.

“You can look at, not only the absolute number of CTCs that you have, but whether or not they have this ability to proliferate and divide,” she said.

The team found that, in some patients, circulating tumor cells rapidly disappeared after surgery, while in others the cells persisted months afterward.

Researchers do not yet know whether the persistence or disappearance of the circulating tumor cells have a role in cancer recurrence, Stott said, stressing that this was an early pilot study.

“We’re scaling up ... enrolling more patients to get a larger scale-critical study going to figure out what this means,” she said.

---
By JoAnne Allen

WASHINGTON (Reuters)

RELATED STORIES:
New drug slows advanced kidney cancer   The role of genes in the development of non-Hodgkin’s lymphomas   Immunotherapy for tumors key topic at cancer meeting   Europe aims to reduce cancer deaths by 15 pct by 2020   Novel light-sensitive compounds show promise for cancer therapy   Symposium on Minimally Invasive Cancer Treatments   Harmless soil-dwelling bacteria successfully kill cancer   Low Molecular Weight Heparin Use in Cancer Treatment   Moving to U.S. tied to higher cancer risks   Tackling a Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes   Cancer costs highest for individually insured   Study Helps Explain Fundamental Process of Tumor Growth   New tool to speed cancer therapy approval available   Is Grilling Linked to Cancer?   Cancer patients often forget details of doctor visit   Discovery of a new mechanism of gene control that is associated with cancer   Research Team Identifies Novel Anti-Cancer Drug from the Sea   Many parents at-risk for cancer disclose genetic test results to children   Biochemist uses computer models to study protein involved with cancer, aging and chronic disease   Diabetes can increase the risk of developing hepatocellular carcinoma   Quality of life with cancer can be preserved   New Research Suggests Ways to Improve Cancer Therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]